Lei Zhou

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl et al. · The Lancet Oncology · 2022 · 256 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Zanubrutinib Versus Bendamustine +10

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 176 citations

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 143 citations · Full text

Long-term Efficacy, Pathology, Pharmacotherapy +17

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

Constantine S. Tam, Meletios Α. Dimopoulos, Ramón García‐Sánz et al. · Blood Advances · 2021 · 83 citations · Full text

Bisphenol AP is anti-estrogenic and may cause adverse effects at low doses relevant to human exposure

Xuan Xiao, Junyu Li, Tong Yu et al. · Environmental Pollution · 2018 · 52 citations

Endocrine Disruptors, Hormonal Contraceptive, Medicine +9